Source: Health Canada shortage reports · Updated Jul 9, 2026
Some Risedronate products are in shortage in Canada (3 of 23 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer.
A bisphosphonate used to treat and prevent osteoporosis (bone thinning).
Products affected
3 / 23
In shortage since
Mar 5, 2019
Reports on file
80
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
JAMP-RISEDRONATE
35MG · TABLET · JAMP PHARMA CORPORATION
DIN 02368552 · since Nov 1, 2019, est. end Dec 30, 2022 · Supply Issues
Active shortage
AURO-RISEDRONATE
150MG · TABLET · AURO PHARMA INC
DIN 02442760 · since Mar 5, 2019, no end estimate · Disruption of the manufacture of the drug.
Active shortage
ACTONEL
5MG · TABLET · ALLERGAN PHARMA CO.
DIN 02242518 · since ?, no end estimate
Resolved
TEVA-RISEDRONATE
150MG · TABLET · TEVA CANADA LIMITED
DIN 02413809 · ended Jun 16, 2026 · Disruption of the manufacture of the drug.
Resolved
TEVA-RISEDRONATE
5MG · TABLET · TEVA CANADA LIMITED
DIN 02298376 · ended Jun 3, 2026 · Disruption of the manufacture of the drug.
Resolved
RISEDRONATE
150MG · TABLET · SANIS HEALTH INC
DIN 02528460 · ended Apr 28, 2026 · Disruption of the manufacture of the drug.
Resolved
RISEDRONATE
35MG · TABLET · SANIS HEALTH INC
DIN 02370255 · ended Mar 25, 2026 · Disruption of the manufacture of the drug.
Resolved
TEVA-RISEDRONATE
5MG · TABLET · TEVA CANADA LIMITED
DIN 02298376 · ended Jul 2, 2025 · Disruption of the manufacture of the drug.
Discontinued
TEVA-RISEDRONATE
30MG · TABLET · TEVA CANADA LIMITED
DIN 02298384
Discontinued
TEVA-RISEDRONATE
30MG · TABLET · TEVA CANADA LIMITED
DIN 02298384
Resolved
TEVA-RISEDRONATE
30MG · TABLET · TEVA CANADA LIMITED
DIN 02298384 · ended Apr 7, 2025 · Disruption of the manufacture of the drug.
Resolved
AA-RISEDRONATE DR
35MG · TABLET (DELAYED-RELEASE) · AA PHARMA INC
DIN 02493268 · ended Mar 11, 2025 · Disruption of the manufacture of the drug.
Showing 12 of 60 reports. All reports are on file with Health Canada.
What's happening
Risedronate is currently affected by 3 active shortage reports filed with Health Canada by JAMP PHARMA CORPORATION, AURO PHARMA INC, ALLERGAN PHARMA CO..
The reported causes are: supply issues; disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Risedronate is classified under “DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION” (ATC M05BA).
Recent changes
No changes recorded yet.
Common questions
What is Risedronate used for?
A bisphosphonate used to treat and prevent osteoporosis (bone thinning).
When will Risedronate be back in stock in Canada?
Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.
Why is Risedronate in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.